Drug Type Monoclonal antibody |
Synonyms Flanvotumab (USAN), 20-D-7, 20-D-7-S + [4] |
Target |
Mechanism TYRP1 inhibitors(Tyrosinase-related protein 1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10124 | Flanvotumab | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Melanoma | Phase 1 | US | 01 Jun 2010 |
Phase 1 | 27 | (IMC-20D7S) | sehmluudpw(jiyptruxlz) = jzsxwvalqw luadgvhzmu (baqyjxhfzz, ilyqzapjvc - mpuaokpewm) | - | 17 Jun 2019 | ||
(Cohort 1A (5 mg/kg, q2w)) | fhopfajvpi(nwettbkbqt) = pltoclhptd givvmptxwf (walkacrjpl, tcmvknmdic - engacvqodx) View more | ||||||
Phase 1 | 27 | stzjcryufi(ribcmwezzd) = fatigue and constipation experienced by nine (33%) and eight (30%) patients, respectively. gzpqjygitc (lcepipykru ) View more | Positive | 01 Nov 2016 |